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Abstract
The identification of HIV-1 envelope glycoprotein (Env) structures that can generate broadly neutralizing antibodies (BNAbs)
is pivotal to the development of a successful vaccine against HIV-1 aimed at eliciting effective humoral immune responses.
To that end, the production of novel Env structure(s) that might induce BNAbs by presentation of conserved epitopes,
which are otherwise occluded, is critical. Here, we focus on a structure that stabilizes Env in a conformation representative
of its primary (CD4) receptor-bound state, thereby exposing highly conserved ‘‘CD4 induced’’ (CD4i) epitope(s) known to be
important for co-receptor binding and subsequent virus infection. A CD4-mimetic miniprotein, miniCD4 (M64U1-SH), was
produced and covalently complexed to recombinant, trimeric gp140 envelope glycoprotein (gp140) using site-specific
disulfide linkages. The resulting gp140-miniCD4 (gp140-S-S-M64U1) complex was recognized by CD4i antibodies and the
HIV-1 co-receptor, CCR5. The gp140-miniCD4 complex elicited the highest titers of CD4i binding antibodies as well as
enhanced neutralizing antibodies against Tier 1 viruses as compared to gp140 protein alone following immunization of
rabbits. Neutralization against HIV-27312/V434M and additional serum mapping confirm the specific elicitation of antibodies
directed to the CD4i epitope(s). These results demonstrate the utility of structure-based approach in improving
immunogenic response against specific region, such as the CD4i epitope(s) here, and its potential role in vaccine
application.
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Introduction
The human immunodeficiency virus type 1 (HIV-1) envelope
glycoprotein (Env) is the lone viral gene product exposed on surface
of the virus and therefore is the major target of HIV-1-specific
neutralizing antibodies (NAbs). This trimeric glycoprotein mediates
receptor binding and viral entry through its interactions with both
CD4 and CCR5/CXCR4. These characteristics make Env a logical
candidate as a component of an HIV-1 vaccine. Such a vaccine will
likely need to elicit broadly cross-neutralizing antibodies to be
effective. However, due to extensive intra- and inter-subtype
sequence variability of Env, anti-Env antibody response are
generally isolate-specific. To be effective against diverse isolates,
the NAbs induced by a prospective vaccine will need to recognize
multiple Env variants, as patients are unlikely to encounter viruses
that match the vaccine strain during natural infection. Therefore,
the ideal method of generating a broad, cross-reactive NAb
response would be to target highly conserved regions in Env [1].
Unfortunately, many conserved epitopes of Env are occluded or
transiently exposed, and therefore are poorly immunogenic. Several
monoclonal antibodies (MAbs) have been isolated from patients
with broad, potent-neutralizing activity [2,3,4,5,6,7], however
attempts to elicit similarly potent and broadly NAbs by vaccination
using recombinant forms of Env as antigens have, at best, met
limited success [8,9]. The antibodies generated in this manner are
primarily strain-specific and have limited breadth in their
neutralizing activity. Designing immunogens that are able to elicit
antibodies that are broadly cross-neutralizing is a challenge as
accessible immunodominant variable regions redirect antibody
responses away from the desired, but often masked conserved
regions [1,10,11,12,13]. Thus, many studies involving Env have
focused on attempting to dampen the immunogenicity of the highly
variable regions and/or to increase the immunogenicity of the
desired conserved epitopes [8,14,15,16].
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One such conserved region that has been under evaluation is
the conformational epitope that Env forms upon binding with the
receptor CD4. This CD4-induced (CD4i) epitope is highly
conserved [10]. In fact, many CD4i antibodies are quite potent,
even against the highly divergent HIV-2, in the presence of sCD4,
indicating the conserved nature of this epitope [10]. This make the
CD4i epitope(s) an attractive target for vaccine development. A
potential concern that CD4i antibodies, as whole IgG, face steric
hindrance in accessing the epitope [17] and hence not effective in
neutralizing primary isolates remain. However, broadly cross-
reactive neutralizing antibodies were elicited in rhesus macaques
by using covalently cross-linked HIV-1 Env-CD4 receptor
complexes [18]. DeVico et al. also showed in a SHIV-challenged
model that antibodies to CD4i sites in HIV-1 gp120 correlated
with the control of SHIV challenge in macaques vaccinated with
cross-linked and single-chain gp120–CD4 complexes [19]. Impor-
tantly, it was shown recently that humans infected with HIV-1
generate CD4i antibodies during the course of infection
[20,21,22,23]. Additionally, it was observed that there is a
correlation between the presence of CD4i NAbs and protection
from disease [19,22]. Also in human clinical trials focusing on
induction of Env-specific antibodies, either using protein alone,
viral vector prime-protein boost or DNA prime-protein boost,
analysis of serum antibody response show elicitation of neutral-
izing antibodies to CD4i sites [24,25]. Therefore, in an effort to
create improved Env antigens that would effectively display cryptic
CD4i epitope(s) without using the native CD4 molecule, which
could present safety concerns in a vaccine preparation due to
potential autoimmune reactions, studies using peptide mimetics of
CD4 were performed [26,27,28,29]. These were based on the
scyllatoxin-scaffold and several generations were evaluated to
define the optimal molecule for use in complex with HIV-1 Env
[26,27,28,29]. Using the most advanced of these CD4-mimetic
miniprotein (miniCD4), M64U1-SH, to generate stable site-
directed disulfide-linked complexes with SF162 gp120 or oligo-
meric V2 loop-deleted gp140 (gp140DV2), the MAb and CCR5
binding profiles were found to be analogous to those obtained
using the same Env antigens bound to soluble CD4 [27]. In the
present study, the immunogenicity of a stably cross-linked gp140-
miniCD4 (gp140-S-S-M64U1) complex was evaluated to deter-
mine the merit of this approach for the elicitation of antibodies




The study was fully approved (approval no. 09 NVD
044.3.3.09) by the Institutional Animal Care and Use Committee
at Novartis in accordance with the requirements for the humane
care and use of animals as set forth in the Animal Welfare Act, the
Institute for Laboratory Animal Research (ILAR) Guide for the
care and use of laboratory animals, and all applicable local, state
and federal laws and regulations.
Reagents
Monoclonal antibodies (MAbs), b12, 2G12, 2F5 and 4E10 were
purchased from Polymun Scientific (Vienna, Austria). MAb 17b
was kindly provided by Dr. James Robinson. The biotinylated
tyrosine-sulfated (at positions 10 and 14) N-terminal 22-mer
CCR5 peptide [30,31] and control biotinylated, non-sulfated, N-
terminal 22-mer CCR5 peptide were purchased from American
Peptide Co. (Sunnyvale, CA). Soluble CD4 (sCD4) was purchased
from Progenics Pharmaceuticals (Tarrytown, NY).
Generation and characterization of Env proteins
Two forms of recombinant HIV-1 Envs were used in this study:
gp140 (and its cross-linking or mixing with miniCD4 to form the
complex) as immunogens and gp120 for in vitro serum mapping
analysis. Both recombinant Envs, gp140 and gp120, were derived
from subtype B CCR5-tropic strain HIV-1SF162. The gp120
glycoprotein is discussed in later section. The oligomeric gp140
glycoprotein contained a 30 amino acid deletion in the V2 loop
region, as described previously [16,32], and were produced in
stable CHO-cell lines [32]. The gp140 glycoprotein was purified
using a three-step purification process involving Galanthus Nivalis-
Agarose (GNA) affinity column, cation exchange DEAE column
and a final ceramic hydroxyapatite (CHAP) column as described
by Srivastava et al. [33]. The purified gp140 glycoprotein was then
analyzed by SDS-PAGE for level of purity and immunoblot for
specific reactivity (to anti-SF162 gp140 polyclonal rabbit sera).
The purity and homogeneity of purified gp140 glycoprotein, as
determined by SDS-PAGE, was .98%. Using Surface Plasmon
Resonance (SPR) (BIAcore 3000), the binding of gp140 glycopro-
tein to sCD4, MAbs b12 and 2G12, were analyzed, as previously
described [34].
For serum mapping, various gp120 glycoproteins were also
generated and characterized. Using transient transfection of
HEK293T cell lines, the following gp120 glycoproteins were
produced: gp120wt (wild-type), gp120DV1V2 (V1V2 deleted),
gp120DV3 (V3 deleted), gp120D368R (CD4-binding site mutant)
and gp120I420R (CD4i-binding site mutant). 48 h post-transfec-
tion, supernatants were collected and clarified off cellular debris
via high-speed centrifugation and concentrated approximately 10-
fold using 100 kDa-cut off membrane filter. The concentrated
materials were stored at 280uC in presence of 1 mM EDTA,
1 mM EGTA and complete protease inhibitor cocktail (Boehrin-
ger-Mannheim). The concentrated supernatants were later thawed
at 4uC and purified, as described above. The purified gp120
glycoproteins were then analyzed by SDS-PAGE for level of purity
and immunoblot for specific reactivity (to anti-SF162 gp140
polyclonal rabbit sera). Both data showed that there was no major
aggregation, degradation or proteolysis and that the purified
gp120 glycoproteins were homogeneous and the level of purity was
.98%.
All the gp120 glycoproteins, wild-type and mutants, were then
subjected to SPR binding analysis for characterizing their
antigenic profiles. All assays were performed at 25uC using
HBS-EP buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM
EDTA, 0.005% [v/v] Surfactant P20; BIAcore, Uppsala,
Sweden), which was degassed for 1 h before use. Approximately
3000 RUs of CD4-IgG2 and MAbs (b12 – CD4BS; 2G12 –
glycan-specific; 3019a, 2557 – anti-V3 and 17b – CD4i) were
immobilized via amine coupling on a CM5 sensor chip using
manufacturer’s protocol, as described elsewhere [34]. 100 nM of
gp120, wild-type or mutant, were injected at 10 ml/minute and
binding to various ligands analyzed. Following each run, the
sensor surface was regenerated using two 10 ml injections of 5 mM
and 10 mM NaOH. The data were analyzed using BIAevaluation
software 3.2 (BIAcore Inc). To correct for refractive index changes
and instrument noise, the response data from the control mock-
treated flow-cell were subtracted from those obtained from the
experimental flow-cell.
Generation and characterization of miniCD4 and gp140-
miniCD4 complex
The CD4-mimetic miniprotein (miniCD4), M64U1 [28] and
M64U1-SH [27], were synthesized by solid phase methods as
described previously [26,27,29,35]. Cross-linking of gp140-S-S-
CD4i Antibodies Elicited by gp140-miniCD4 Complex
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M64U1 was performed in the following manner: M64U1-SH,
having an additional sulfhydryl group on side chain of Lys4, was
incubated at a molar ratio of 3:1 with SF162 gp140 for 1 h at
room temperature (RT). The additional SH group was introduced
derivatizing the position 4 of the M64U1 peptide [28].
To characterize the gp140-S-S-M64U1 complex for its ability to
bind various MAbs, Surface Plasmon Resonance (SPR) (BIAcore
3000) was used. All assays were performed at 25uC using HBS-EP
buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA,
0.005% [v/v] Surfactant P20; BIAcore, Uppsala, Sweden), which
was degassed for 1 h before use. The flow-rate was maintained at
10 ml/minute. A CM5 sensor chip was used and #1500 Response
Units (RUs) of sCD4 (Progenics Pharmaceuticals, Tarrytown, NY)
or ,3000 RUs of MAbs (b12, 2G12, 17b) were covalently
immobilized via amine coupling using manufacturer’s protocol, as
described elsewhere [34]. For the CCR5 peptide-binding analysis,
800–900 RUs of biotinylated sulfated N-terminal 22-mer CCR5
peptide, [Biotin-CCR5 (SO3)] [30,31], and the control, biotiny-
lated non-sulfated N-terminal 22-mer CCR5 peptide [Biotin-
CCR5 (control)] were immobilized on a streptavidin (SA) sensor
chip; the free streptavidin surface was blocked by biotin. Purified
SF162 gp140 (100 nM) or cross-linked gp140-S-S-M64U1 com-
plex (100 nM) was then injected at 10 ml/minute for binding
analysis. Following each run, the sensor surface was regenerated
using two 10 ml injections of 5 mM and 10 mM NaOH. The data
were analyzed using BIAevaluation software 3.2 (BIAcore Inc). To
correct for refractive index changes and instrument noise, the
response data from the control mock-treated flow-cell were
subtracted from those obtained from the experimental flow-cell.
Rabbit Immunization
Immunization studies were conducted at Josman LLC (Napa,
CA), a research facility that is licensed through the USDA (No. 93-
R-0260) and has a Public Health Service (PHS) Assurance from
the NIH (No. A3404-01). Five female New Zealand White rabbits,
per group, were used in the immunogenicity study. Rabbits were
immunized with M64U1-SH cross-linked with gp140 (gp140-S-S-
M64U1), gp140 mixed with M64U1 (mixed, no cross-linking),
gp140 and M64U1 (miniCD4, as control). Four protein immuni-
zations were administered intramuscularly, in the gluteus, at weeks
0, 4, 12, and 24. The total protein dosage at each immunization
was 50 mg. Proteins were administered in MF59, Novartis’s
proprietary oil-in-water adjuvant. Serum samples were collected
prior to first immunization and two weeks following each
immunization. The study was fully approved (Approval no. 09
NVD 044.3.3.09) by the Institutional Animal Care and Use
Committee at Novartis in accordance with the requirements for
the humane care and use of animals as set forth in the Animal
Welfare Act and the Institute for Laboratory Animal Research
(ILAR) Guide for the care and use of laboratory animals, and all
applicable local, state and federal laws and regulations.
HIV-1 Env pseudovirus neutralization assays
Virus neutralization titers were measured using a well-
standardized assay employing HIV-1 Env pseudoviruses and a
luciferase reporter gene assay in TZM-bl cells [Dr. John C.
Kappes, Dr. Xiaoyun Wu and Tranzyme, Inc. (Durham, NC)] as
described previously [36,37]. Briefly, a total of 200 TCID50
pseudoviruses/well were added to diluted serum samples and
incubated at 37uC for 1 h. Following incubation, 10,000 cells/well
in DEAE-dextran-containing media were added and incubated for
48 h at 37uC. The final concentration of DEAE-dextran was
10 mg/ml. After a 48 h incubation, 100 ml of cells was transferred
to a 96-well black solid plates (CostarH) for measurements of
luminescence using Bright Glo substrate solution as described by
the supplier (Promega). Neutralization titers are the dilution at
which relative luminescence units (RLU) were reduced by 50%
compared to virus control wells after subtraction of background
RLUs. HIV-1 Env pseudoviruses were prepared by co-transfection
of HEK293T cells with expression plasmids containing full-length
molecularly cloned gp160 env genes from a panel of HIV-1 isolates
combined with an env-deficient HIV-1 backbone vector
(pSG3Denv) using FuGENE-6 HD (Roche Applied Sciences,
Indianapolis, IN), as previously reported [36]. After 48 h, the cell
culture supernatants containing the pseudoviruses were filtered
through a 0.45 mm filters and stored at 280uC until use.
HIV-2 neutralization assays
For the detection of CD4i neutralizing antibodies, a modified
neutralization assay was used, as previously described [23].
Antibody avidity measurements
Antibody avidity index determination was performed using an
ammonium thiocyanate (NH4SCN) displacement ELISA, as
described elsewhere [33].
Measuring envelope-specific antibody titers by ELISA
Envelope-specific total antibody titers in sera immunized with
gp140 or cross-linked gp140-miniCD4 (gp140-S-S-M64U1) com-
plex were quantified by a standard ELISA assay, as previously
described [33].
Serum mapping - Generation of antigen-coupled beads
To dissect specificity of antibody response against epitope(s) on
gp140 or the gp140-miniCD4 (cross-linked or mixed) complex, a
‘serum mapping’ assay as described by Y Li et al. [38] was used.
Following the expression, purification and characterization of the
gp120 variants, the proteins including cross-linked gp140-S-S-
M64U1 complex, were coupled to paramagnetic polystyrene,
tosylactivated magnet MyOne Dynabeads (Invitrogen). Coupling
was performed at 37uC for 6–8 h according to the manufacturer’s
instructions, briefly described as follows. 1 mg of protein, which
has been extensively dialyzed against PBS (pH 7.4), was coupled to
50 mg (0.5 ml volume) of paramagnetic beads, in 1.25 ml of
coupling buffer [0.1 M sodium borate buffer (pH 9.5) with 1 M
ammonium sulfate]. The antigen-coupled beads were separated
from the coupling buffer with a magnet. The antigen-coupled
beads were then resuspended with 5 ml of blocking buffer [PBS
(pH 7.4) with 0.5% (w/v) bovine serum albumin (BSA) and 0.05%
(v/v) Tween 20] and incubated at 4uC for 14–16 h. The blocking
buffer was removed by aspiration, and the antigen-coupled beads
were washed extensively with 5 ml of buffer [PBS (pH 7.4) with
0.1% (w/v) BSA and 0.05% (v/v) Tween 20]. Finally, the beads
were resuspended in 0.5 ml of storage buffer [PBS (pH 7.4) with
0.1% (w/v) BSA, 0.05% (v/v) Tween 20, 0.02% (v/v) sodium
azide, and protease inhibitors] and stored at 4uC until further use.
After the generation of antigen-coupled beads, the antigenic
integrity and specificity of each protein were verified by adsorption
of ligands followed by D7324-capture [anti-gp120 C5 region
polyclonal antibodies (Aalto, Dublin, Ireland) at 5 mg/ml] ELISA.
The ligands used during adsorption to validate the antigen-
coupled beads were CD4-IgG2 (against D368R gp120) and MAbs
b12 (against D368R gp120), 2G12 (as control against all gp120s),
17b (I420R gp120 & gp140-S-S-M64U1 complex) and 3019a,
2557 (DV3 gp120). All antigens, including gp140-S-S-M64U1
complex, upon coupling to paramagnetic beads maintained their
characteristic binding profiles and their ability to deplete specific
CD4i Antibodies Elicited by gp140-miniCD4 Complex
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antibody, as observed by ELISA (data not shown). Therefore, the
beads were qualified to be used in subsequent ‘serum mapping’
analysis. BSA-coated beads were also generated using the same
approach, as described above, to be used as negative control for
the solid phase adsorption process.
Serum mapping - Depletion and antibody-binding ELISA
Before adsorption, the gp120 antigen-coupled beads (including
BSA-coated beads, negative control) were washed 2–3 times with
Dulbecco modified Eagle medium (DMEM) containing 10% (v/v)
fetal bovine serum (FBS) and incubated in the same media at room
temperature for 20–30 min to block potential nonspecific binding
to the beads prior to adsorption. Rabbit sera were then diluted 10-
fold in DMEM containing 10% (v/v) FBS; 500 ml of the diluted
sera was incubated with 50 ml of beads at room temperature for
1 h. Following adsorption, the beads were removed from the
treated serum samples with a magnet. The ‘depleted’ serum were
collected and stored at 4uC until subsequent analysis by ELISA.
The antigen-coupled beads were washed twice with PBS (pH 7.4)
containing 500 mM NaCl and once with PBS (pH 7.4). The
bound antibodies were then eluted by a stepwise decrease in pH –
first using 125 ml 100 mM glycine-HCl elution buffer (pH 2.7) for
30 s, separation of the beads with a magnet and then subjecting
the acid-eluted solution containing IgG to a separate tube
containing 1 M Tris (pH 9.0) buffer for neutralization. Subse-
quently, the same procedure was performed using 125 ml 100 mM
glycine-HCl (pH 2.2) to recover any IgG resistant to elution at
pH 2.7. This sample is referred to as ‘adsorbed’ sample.
The presence of gp120-specific antibodies in the adsorbed and
depleted fractions were analyzed by Ab D7324-capture ELISA,
using a protocol described previously [39,40]. The secondary
antibody used was ECLTM Donkey HRP-linked anti-rabbit IgG
(GE Healthcare) and used at 1:10,000 dilutions (100 ml/well). The
optical density (OD) was determined using a microplate reader
(Molecular Devices) at 450 nm.
V3-peptide competition assay
The V3-peptide used in this competition assay was SF162 V3-
cyclic peptide (CTRPNNNTRKSITIGPGRAFYATGDIIGDIR
QAHC) [41]; a V3-scrambled cyclic peptide (CTRPNNNTRKSI-
FYRGAPGITAT GDIIGDIRQAHC) was used as control. The
competition assay was performed as described below. Briefly,
maxisorb (NuncTM) 96-well plates were coated with 100 ml of 2 mg/
ml (200 ng/well) of Ab D7324 [anti-gp120 C5 region polyclonal
antibodies (Aalto, Dublin, Ireland)] in PBS (pH 7.4) and incubated
overnight at 4uC. The plates were then blocked with 200 ml of 1%
(w/v) BSA in PBS (pH 7.4) with incubation at 37uC for 1 h. The
plates were washed three times with wash buffer [PBS
(pH 7.4)+0.1% (v/v) Tween 20]. SF162 gp140 protein was diluted
at 1 mg/ml in dilution buffer [PBS (pH 7.4)+1% (w/v) BSA+0.1%
(v/v) Tween 20] and 100 ml of 1 mg/ml of protein added (100 ng/
well) onto the Ab D7324 coated-plate and incubated at room
temperature for 1 h. The plates were then washed three times with
wash buffer. The rabbit sera were incubated with either V3-cyclic
peptide or V3-scrambled cyclic peptide (control), for 1 h at room
temperature, with varying concentrations of V3-peptide (serial
dilutions in dilution buffer) before their addition to the gp140-
captured ELISA plates. The peptide+sera dilutions were then
incubated at room temperature for 2 h. The plates were then
washed three times with wash buffer and bound anti-Env rabbit
antibodies detected with ECLTM Donkey HRP-linked anti-rabbit
IgG (GEHealthcare) at 1:10,000 dilutions (100 ml/well) followed by
development of the reaction using TMB Microwell Peroxidase
Substrate System (KPL). The percent (%) inhibition, which is the
extent of serum binding to gp140 inhibited by V3-peptide, is
calculated as the ratio of serum binding in presence of V3-cyclic
peptide to serum binding in presence of control peptide6100.
Statistical analyses
Comparisons between multiple groups were carried out using
an analysis of variance (ANOVA). A two-sided Wilcoxon rank sum
analysis was used to test for differences between immunization
groups. For all comparisons, a two-sided P,0.05 was considered
statistically significant. All analyses were performed using the
analysis software within the GraphPad Prism package 5.01.
Results
Based on a preliminary study using the CD4-mimetic miniprotein
(miniCD4), M64U1-SH, coupled to soluble HIV-1 gp120 [27] and
gp140DV2 glycoproteins, the cross-linked gp140-S-S-M64U1 com-
plex was chosen for this study. Since, the SF162 V2-loop deleted
gp140 (gp140DV2) immunogen was previously shown to elicit higher
titers of cross-reactive neutralizing antibodies than SF162 gp140
[32], the modified V2 loop-deleted gp140 (gp140DV2), hereafter
referred to as oligomeric gp140 (gp140), was used for these studies.
The stably cross-linked gp140-miniCD4 (gp140-S-S-
M64U1) complex showed enhanced exposure of CD4i
epitope(s) in vitro
After generation of cross-linked gp140-miniCD4 (gp140-S-S-
M64U1) complex [27], the antigenicity and stability of the
complex was analyzed and compared to that of uncomplexed
gp140 glycoprotein by Surface Plasmon Resonance (SPR) to
measure binding of the complex (and gp140) to covalently
immobilized soluble CD4 (sCD4) or MAbs (b12, 2G12, 17b).
While gp140 bound sCD4, the gp140-S-S-M64U1 complex in
which the CD4BS cavity was occupied by the miniCD4, did not
(Fig. 1A). Similarly, while uncomplexed gp140 bound to MAb b12
with high affinity as expected, the binding of gp140-S-S-M64U1
complex to MAb b12 was reduced by .4-fold, again due to the
miniCD4 occupying the CD4BS of the gp140 (Fig. 1B). Most
importantly, while uncomplexed gp140 bound to the CD4i
epitope specific MAb, 17b, poorly, reflecting relatively little
exposure of this CD4i epitope on the non-receptor bound
gp140; in contrast, the gp140-S-S-M64U1 complex was efficiently
recognized by MAb 17b. The binding of MAb 17b was increased
by .5-fold (Fig. 1C), indicative of the enhanced exposure of the
CD4i epitope(s) in the complex. These data validated the antigenic
state of the complex. Of note, MAb 2G12, a MAb that recognizes
terminal mannose on HIV-1 Env, bound both the complex and
uncomplexed gp140s identically (Fig. 1D).
The binding of gp140-S-S-M64U1 complex to tyrosine-sulfated
CCR5 N-terminal 22-mer peptide [31] was also measured using
an approach described previously [30]. While the gp140-S-S-
M64U1 complex recognized the sulfated CCR5-peptide [biotin-
CCR5 (SO3)] efficiently and specifically (as opposed to non-
sulfated CCR5 peptide, used as control), the gp140 in its native
state did not (Fig. 2A, B). This analysis further support that the
gp140-S-S-M64U1 complex was in a CD4-induced state and was
thus likely a good immunogen with the potential to elicit
antibodies directed toward CD4i epitope(s) on HIV-1 Env.
Elicitation of high titer antigen-specific antibody
responses using gp140 and gp140-miniCD4 complexes
An immunization study was performed in rabbits to test
whether or not the cross-linked gp140-miniCD4 (gp140-S-S-
CD4i Antibodies Elicited by gp140-miniCD4 Complex
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M64U1) complex could elicit Ab responses directed to the
CD4i epitope(s) on the HIV-1Env in an animal model where
there would be an absence of the cognate CD4 receptor ligand
for the HIV-1 Env protein. This type of study would serve as
the strictest test of whether the CD4i sites were being exposed
in vivo as a result of complexing of the gp140 to the CD4-
mimetic miniprotein (miniCD4) as opposed to the natural
receptor molecule as might be expected and has been observed
in non-human primates [17](W Bogers, SW Barnett, et al.,
unpublished results). The scheme of the rabbit immunization is
shown in Fig. 3A. Four protein immunizations were admin-
istered using MF59 adjuvant at 0, 4, 12, and 24 weeks and sera
Figure 1. Binding of cross-linked gp140-miniCD4 (gp140-S-S-M64U1) complex to soluble CD4 and MAbs. Surface Plasmon Resonance
(SPR) binding analysis of cross-linked gp140-miniCD4 (gp140-S-S-M64U1) complex, in comparison to uncomplexed gp140, to ligands immobilized on
CM5 sensor chip: (A) soluble CD4 (sCD4), (B) (CD4 binding site), (C) MAb 2G12 (glycans), and (D) MAb 17b (CD4i site).
doi:10.1371/journal.pone.0030233.g001
Figure 2. Binding of cross-linked gp140-miniCD4 (gp140-S-S-M64U1) complex to CCR5 peptide. Surface Plasmon Resonance (SPR)
binding analysis of (A) gp140 and (B) cross-linked gp140-miniCD4 (gp140-S-S-M64U1) complex to two ligands immobilized on CM5 sensor chip:
biotinylated, tyrosine-sulfated (at positions 10 and 14) 22-mer N-terminal CCR5 peptide [biotin-CCR5(SO3)] [30,31] and a control, biotinylated non-
sulfated 22-mer N-terminal CCR5 peptide [biotin-CCR5 (control)].
doi:10.1371/journal.pone.0030233.g002
CD4i Antibodies Elicited by gp140-miniCD4 Complex
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were collected post-immunization at intervals, as indicated in
Fig. 3A.
To determine the level of gp140-specific antibodies that were
generated by immunization, serum samples were collected before
immunization (pre-immune sera) and 2-weeks following each
immunization, including 4-weeks after last immunization, and
analyzed by ELISA. Sera from all immunization groups elicited
antibodies that recognized gp140 above the background pre-
immunization levels following the initial immunization (Fig. 3B).
Binding titers were increased with additional immunizations and
achieved the highest titers two weeks following the third (2wp3) or
fourth (2wp4) immunization for all groups, except M64U1
(miniCD4) group that was used as a control. In animals
immunized with M64U1 (miniCD4), gp140-specific antibody
titers did not increase beyond the basal level (Fig. 3B, shown by
the dotted line) observed for the pre-immune sera.
Most noteworthy, when the total anti-gp140 binding antibodies
were analyzed by ELISA, a,10-fold increase was observed between
the titers generated by cross-linked gp140-S-S-M64U1 complex in
comparison to gp140 alone. At two-weeks post-fourth immunization
(2wp4), while gp140 elicited a binding antibody titer of ,106, the
cross-linked gp140-S-S-M64U1 complex generated titers about a
log higher (,107) reaching statistical significance [for 2wp4 sera,
gp140 vs. gp140-S-S-M64U1 (cross-linked), p= 0.0079; gp140 vs.
gp140+M64U1 (mixed), p= 0.0556]. The gp140+M64U1 (mixed)
complex on the other hand elicited antibody titers ($106) to a level
that was not statistically different from those elicited by gp140 alone,
but were lower than those generated by the cross-linked gp140-S-S-
M64U1 complex at 2wp4 (Fig. 3B). As expected, M64U1 (miniCD4)
itself did not generate gp140-specific binding antibody responses.
The avidity of gp140-specific serum antibodies was also
measured using an ammonium thiocyanate (NH4SCN) ELISA
(Fig. 3C) to estimate the extent of antibody maturation. Antibody
avidity was similar two weeks following third (2wp3) or fourth
(2wp4) immunizations (P.0.05 all groups except the M64U1
(miniCD4)-immunized group), although subtle increases were
observed for both the gp140-miniCD4 [gp140-S-S-M64U1 (cross-
linked) and gp140+M64U1 (mixed)] complex regimens between
these two time points. The slightly higher avidities could
potentially account for the improved virus neutralization seen
with 2wp3/2wp4 sera from the gp140-miniCD4 (cross-linked or
mixed) complexes (see below; Fig. 4). Four immunizations, with
gp140 or the gp140-miniCD4 (cross-linked or mixed) complexes,
elicited serum antibodies with the highest avidity (Fig. 3C).
Immunization of rabbits with cross-linked gp140-
miniCD4 (gp140-S-S-M64U1) complex elicited higher titer
and broader HIV-1 neutralizing antibody responses than
immunization with gp140 alone
Sera collected two weeks following the third (p3) and fourth (p4)
immunizations were analyzed for their capacity to neutralize the
Figure 3. Rabbit study design and antibody binding analysis of vaccine sera. (A) Scheme of vaccination study in rabbits, showing time-
point of administration of immunogens and collection of sera for evaluation. (B & C) SF162 gp140-specific binding antibody responses induced by
various immunogens [gp140, M64U1 (miniCD4), gp140-S-S-M64U1 (cross-linked), or gp140+M64U1 (mixed)] in rabbit sera. Two weeks following the
second (2wp2), third (2wp3) and fourth (2wp4) immunizations, individual sera were analyzed via ELISA and group geometric mean (geomean) titers
calculated. Pre-immune sera were also evaluated to identify the level of non-specific reactivity. (B) Avidity of SF162 gp140-specific antibodies from the
four groups of animals at 2wp2, 2wp3 and 2wp4 following immunization.
doi:10.1371/journal.pone.0030233.g003
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homologous SF162 strain and a select panel of tiered heterologous
HIV-1 Env pseudoviruses (Fig. 4). Sera were examined using the
well-standardized pseudovirus-based TZM-bl reporter assay, as
described in materials and methods. Sera obtained from rabbits
immunized with the miniCD4 (M64U1) alone did not display
neutralizing activity against any of the viruses at the maximum
concentration tested (dilution of 1:25) (Fig. 4). However, all
remaining groups showed SF162 neutralization titers of .25, at
both time-points tested (Fig. 3). Neutralizing titers increased
following subsequent immunizations (p4.p3) with the gp140-S-S-
M64U1 (cross-linked) or gp140+M64U1 (mixed) complex, but not
with gp140 where the titers remained unchanged following fourth
protein administration. Interestingly, groups immunized with the
cross-linked or mixed gp140-miniCD4 complexes elicited higher
SF162 neutralizing titers than groups immunized with gp140
alone, more so using the cross-linked complex (for 2wp4 sera,
gp140 vs. both groups of complexes, p = 0.0127; gp140 vs. cross-
linked group only, p = 0.0159. Fig. 4). This was also similar with
regard to the neutralization of other Tier 1A virus, Subtype B
HxB2 and Subtype C MW965.26, where the fourth immunization
elicited higher neutralizing titers in all groups (except the control
group, miniCD4). When the sera were evaluated for neutralization
of Tier 1B viruses (Subtype B BaL.26 and SS1196.1), animals
immunized with the cross-linked complex generated the highest
titers of neutralizing antibodies following fourth immunization.
When Tier 2 viruses (Subtype B 6535.3, QH0692.42,
RHPA4259.7) were tested, the titers of neutralizing antibodies
generated were very low or not measurable. Except for
neutralization of 6535.3 pseudoviruses by sera of animals
immunized with the gp140-miniCD4 complex (both cross-linked
and mixed), no other sera showed any neutralization activity
against Tier 2 viruses. None of the sera neutralized QH0692.42 or
RHPA4259.7 pseudoviruses.
As expected, most of the immune sera tested did not neutralize
MLV, here used as a control, except for low, non-specific
neutralization by 2wp3 gp140-immunized sera (Fig. 4). Due to
this observation, we negated the minimal neutralization of 6535.3
and QH0692.42 viruses by the same (gp140-immunized) sera.
When comparing the neutralization of Tier 1A (SF162, HxB2,
and MW965.26) pseudoviruses, the IC50 values of 2wp3/2wp4
sera from the cross-linked complex were significantly higher for
SF162 as compared to either of the mixed complex or gp140 alone
Figure 4. Neutralization of a panel of tiered HIV-1 Env pseudoviruses by vaccine sera. Analysis of breadth by neutralization of various
tiered HIV-1 Env pseudoviruses by 2wp3 (p3) and 2wp4 (p4) sera from animals immunized with gp140 (open black circles, filled black circles),
miniCD4 (M64U1) (open black triangles, filled black triangles) and two forms of the gp140-miniCD4 complexes: cross-linked (gp140-S-S-M64U1) (open
blue circles, filled blue circles) and mixed (gp140+M64U1) (open red circles, filled red circles). ID50 neutralization titers are indicated against different
viral isolates: SF162.LS, HxB2, MW965.26, BaL.26, SS1196.1, 6535.3, QH0692.42 and RHPA4259.7. The tiered categorization of the HIV-1 Env
pseudoviruses is indicated. The subtypes are indicated within parenthesis. Neutralization of MLV is shown here as a control.
doi:10.1371/journal.pone.0030233.g004
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[cross-linked vs. mixed: p3= 0.0317 & p4=0.1508; cross-linked
vs. gp140: p3= 0.0159 (Fig. 4)]. HxB2 and MW965.26 neutral-
ization titers using 2wp3 and 2wp4 sera showed no significant
differences between groups. HxB2, despite being a lab-adapted
Tier 1A virus, is not highly sensitive to anti-V3 antibodies. The
HxB2 V3 loop contains a rare dipeptide insert (Gln-Arg)
immediately adjacent to the Gly-Pro-Gly-Arg (GPGR) sequence
at the V3 crown, a region highly targeted by antibodies generated
during natural infection and upon vaccination by Env proteins
[42]. Therefore, the improved neutralization of HxB2 virus by the
sera from the cross-linked complex group (Fig. 4) indicated that the
neutralization observed here was not primarily due to anti-V3
antibodies. To address this further, ‘epitope mapping’ experiments
were performed and are described in section below.
The 2wp3/2wp4 sera from the cross-linked complex also
neutralized the Tier 1B viruses consistently better than the sera
from mixed complex or from gp140 alone. The IC50 values, for
the Tier 1B neutralization by sera from cross-linked complex, were
.1–2 log lower when compared to that from Tier 1A
neutralization (Fig. 4). In case of Tier 2 viruses, only sera from
the mixed complex (both 2wp3 and 2wp4) gave consistent,
although low, neutralization of 6535.3 virus; the other Tier 2
viruses were not consistently neutralized by any sera (Fig. 4).
Overall, it was evident that the 2wp3/2wp4 sera from the rabbits
immunized with the cross-linked complex was most potent in
neutralizing the various tiered HIV-1 isolates.
Overall, immunization with the cross-linked gp140-miniCD4
(gp140-S-S-M64U1) complex resulted in an increase in the
breadth of HIV neutralization as compare to immunization with
uncomplexed gp140 protein. Sera from animals immunized with
the cross-linked complex neutralized the majority of pseudoviruses
tested in the panel with neutralizing titers higher than sera from
other groups. The sera from rabbits immunized with the mixed
(gp140+M64U1) complex also neutralized .50% of the heterol-
ogous viruses, including one Tier1B and Tier 2 virus, albeit with
low potency. In contrast, sera immunized with gp140 only
neutralized the Tier 1A, SF162 and MW965.26, viruses.
The cross-linked gp140-miniCD4 (gp140-S-S-M64U1)
complex elicited binding antibodies directed against
CD4i epitope(s) on HIV-1 Env
2wp4 sera were evaluated for specificities of antibodies elicited,
using an ‘epitope mapping’ approach described previously [22].
Various forms of monomeric gp120, wild-type and mutants, were
purified to .95% purity using method described previously [33].
Amongst the mutant gp120s, we generated the following:
gp120D368R, a CD4BS mutant [43,44,45]; gp120I420R, a
CD4i site mutant [46,47], gp120DV3 (V3 deleted) and
gp120DV1V2 (V1V2 deleted). The ability of the mutant gp120s,
in comparison to wild-type, to exclude binding to known MAb was
screened using SPR (data not shown). Here, we used both
gp120I420R (CD4i site mutant) and cross-linked gp140-S-S-
M64U1 complex (exposing CD4i epitopes) with the hypothesis
that the two reagents could provide complementary information to
validate the specificity of antibodies generated against the CD4i
epitope(s). All gp120s and cross-linked gp140-S-S-M64U1 com-
plex were then covalently coupled to Dynabeads (as described in
Materials and Methods). Following coupling, the bead-coupled
antigens were tested to determine their specificities to bind or
abrogate recognition of well-characterized MAbs. For example,
gp120DV3-coupled beads bound MAb 2G12, MAb b12, CD4-
IgG2 and MAb 17b (in presence of sCD4), but not anti-V3 MAbs,
3109a and 2257; gp120I420R-coupled beads bound all above
MAbs except 17b, in presence of sCD4; gp120D368R-coupled
beads bound all above MAbs except CD4-IgG2 and MAb b12
(data not shown).
Rabbit sera from various groups were then subjected to
differential solid-phase adsorption. From the gp140-immunized
group, 2wp4-sera were selected from two animals showing the
highest neutralization titers. From the group immunized with the
cross-linked gp140-S-S-M64U1 complex, 2wp4-sera from all five
rabbits were selected, whereas 2wp4-sera from only two animals
were selected from the groups immunized with gp140+M64U1
(mixed) complex and gp140 alone. Sera from rabbits immunized
with M64U1 (miniCD4) alone were not analyzed due to their lack
of binding and neutralizing potency.
Upon adsorption, sera from animals immunized with gp140
generated antibodies predominantly directed to the gp120 subunit,
evident by near-complete depletion of binding antibodies by
gp120DV1V2-coupled beads (Fig. 5A). A proportion of these
antibodies was V3-specific, and therefore could not be depleted by
gp120DV3 proteins. Interestingly, sera from gp140-immunized
animals also elicited substantial levels of anti-CD4BS antibodies.
Post-adsorption of the sera with beads containing gp120D368R, a
CD4BS mutant, a noteworthy level of antibodies remained in the
depleted fraction, primarily due to their inability to bind to
CD4BS (Fig. 5A). The depleted sera, but not the adsorbed
fraction, were found to partially compete with CD4-IgG2 and
CD4BS-MAbs when analyzed using SPR (data not shown),
confirming their CD4BS-specificty. These sera from gp140-
immunized rabbits, when treated with cross-linked gp140-S-S-
M64U1 complex-coupled beads, could not be fully depleted of
gp120-specific antibodies, highlighting that the depleted fraction
still contained levels of non-CD4i antibodies (Fig. 5A). This also
indicates that specific elicitation of CD4i antibodies was not
feasible using gp140 alone.
The sera from animals immunized with gp140+M64U1
(mixed) complex and gp140 did not elicit substantial levels of
CD4i antibodies. This was evident by comparing the adsorption
of sera by both the gp120I420R-coupled and cross-linked gp140-
S-S-M64U1 complex-coupled beads (Fig. 5C). All the binding
antibodies in the sera were completely adsorbed by gp120I420R,
indicating possible lack of antibodies to CD4i-site, whereas the
depleted fraction showed no binding antibodies. On the other
hand, upon adsorption using the complex-coupled-beads, binding
antibodies were detected in both the adsorbed and depleted
fractions (Fig. 5C). Taken together, these results indicated that
this immunogen elicited low levels of CD4i-antibodies (also see
Fig. 6). Some of the Abs in the sera was directed to the V3-region
(Fig. 5C) and no CD4BS-antibodies were induced (data not
shown).
When sera from the animals immunized with cross-linked
gp140-S-S-M64U1 complex were analyzed, the predominant
response was against CD4i epitope(s), and to some extent to the
V3 loop (Fig. 5B). Interestingly, gp120I420R and gp140-S-S-
M64U1complex-coupled beads generated complementary data,
confirming the elicitation of CD4i antibody response in this group
of rabbits (Fig. 5B). Gp120I420R-coupled beads failed to
completely deplete gp120-reactive antibodies (Fig. 5B), whereas
cross-linked gp140-S-S-M64U1 complex-coupled beads managed
to do so. In the case of gp120I420R-coupled beads, both the
adsorbed and depleted fractions showed significant amounts of
gp120-specific antibodies, with CD4i antibodies dominating the
depleted fraction. In sera treated with cross-linked gp140-S-S-
M64U1 complex-coupled beads, all the gp120-specific antibodies
fractionated in the adsorbed fraction, affirming the pull-down of
antibodies to other gp120-epitopes including CD4i site which is
readily exposed in this complex (Fig. 5B).
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Bovine Serum Albumin (BSA)-coupled beads were used as
control to show the specificity of adsorption. None of the sera
displayed any non-specific adsorption to BSA (left panel, Fig. 5A,
B, C).
Finally, to evaluate the relative levels of anti-V3 antibodies
elicited by the three immunogens - gp140, gp140-S-S-M64U1
(cross-linked) and gp140+M64U1 (mixed), a V3-peptide compe-
tition assay was performed. Results showed that .80% of the
binding activity to SF162 gp140 from the gp140-immunized sera
could be inhibited by V3-cyclic peptide (left panel, Fig. 5D).
Whereas, under similar conditions, #20% of the binding to gp140
from the two gp140-miniCD4 complex-immunized groups
Figure 5. Serum-mapping analysis. Determining epitope-specificity of sera using (A–C) a differential solid-phase adsorption method [38], and (D)
V3-cyclic peptide competition assay. A representative profile of the antibody-specificity generated by sera from each of the groups is shown upon
adsorption by the various antigen-coupled beads, as described in Material and Methods. Specificity of sera from group immunized with (A) gp140, (B)
cross-linked gp140-S-S-M64U1 complex and (C) mixed gp140+M64U1 complex. The epitopes are highlighted atop each panel in grey. The beads
(BSA-beads; black/grey curves) used as ‘control’ are shown on the first column. The second column shows specificity to ‘CD4BS’-eptiope (using
gp120D368R-beads; green curves) for gp140 immunized group and ‘CD4i’ epitope (using gp140-S-S-M64U1 complex; purple curves) for cross-linked or
mixed gp140-miniCD4 complex immunized groups; the third column shows specificity for ‘V1V2’-loop (using gp120DV1V2-beads; orange curves) for
gp140 immunized group and ‘CD4i’ epitope (using gp120I420R-beads; cyan curves) for cross-linked or mixed gp140-miniCD4 complex immunized
groups. The final column shows specificity to ‘V3’-loop (using gp120DV3-beads; blue curves). (D) Competition assay to inhibit binding of gp140 (left
panel) and gp140-miniCD4 complex, cross-linked gp140-S-S-M64U1 (middle panel) or mixed gp140+M64U1 (right panel), immunized rabbit sera to
gp140 by V3-cyclic peptide. As control, a V3-scrambled cyclic peptide was used (see Materials & Methods for details). The percent (%) inhibition,
which is the extent of serum binding to gp140 inhibited by V3-peptide, is calculated as the ratio of serum binding in presence of V3-cyclic peptide to
serum binding in presence of control peptide6100.
doi:10.1371/journal.pone.0030233.g005
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[gp140-S-S-M64U1 (cross-linked) and gp140+M64U1 (mixed)]
(middle and right panel, respectively, Fig. 5D) was inhibited by the
V3-cyclic peptide, except for sera from one animal (Ra#16,
gp140+M64U1immunized group) which showed $40% inhibition
at the highest V3-peptide concentration tested (right panel,
Fig. 5D). This indicated that elicitation of anti-V3 antibodies
was more pronounced following immunization with the gp140
immunogen as compared to the gp140-miniCD4 [gp140-S-S-
M64U1 (cross-linked) and gp140+M64U1 (mixed)] complex
immunogens.
The cross-linked gp140-miniCD4 (gp140-S-S-M64U1)
complex elicited high levels of antibodies directed
against CD4i site that neutralized HIV-27312A/V434M in the
presence of sCD4
Sera were next analyzed for the presence of virus neutralizing
antibodies directed against the highly conserved CD4i site by
testing their capacity to neutralize HIV-2 in the presence and
absence of soluble CD4 (sCD4) [10]. Individual rabbit sera were
tested from the pre-immune, 2wp3, and 2wp4 time points and the
ID50 neutralizing titers determined (Fig. 6). In the gp140 group,
serum from only a single rabbit (rabbit numbered 5) displayed
ID50 titers of$2-log against the HIV-27312A/V434M pseudovirus in
presence of sCD4, at 2wp3. However, at 2wp4, this CD4i
neutralization was lost (Fig. 6A). As expected, none of the sera
from the M64U1 (miniCD4)-immunized (control) group neutral-
ized HIV-2 (Fig. 6B). Importantly, all animals immunized with the
cross-linked gp140-S-S-M64U1 complex elicited highest neutral-
izing titers at 2wp3, with only modest improvement at 2wp4. 5/5
animals in this group neutralized HIV-27312A/V434M pseudovirus
in presence of sCD4 with ID50 tiers of $4-logs, with rabbits
numbered 14 and 15 showing the higher virus neutralization
activities (Fig. 6C), confirming elicitation of strong CD4i anti-
body responses. In contrast, the rabbits that received the
gp140+M64U1 (mixed) complex did not elicit comparable levels
of CD4i antibodies, with only one rabbit (numbered 19) at 2wp4
that displayed an ID50 titer of 3–4 log (Fig. 6D).
These results indicated that generation of a stable complex of
gp140-miniCD4 such as the cross-linked gp140-S-S-M64U1,
rather than short-term mixing of the two proteins, was the best
practical approach to elicit highest levels of CD4i neutralizing
antibodies in this animal model.
Discussion
Recent studies evaluating the evolution and specificities of
broadly-neutralizing antibodies during HIV-1 infection [22,23,48]
have provided important insights regarding the significance of CD4i
antibodies and their potential role in vaccine against HIV-1. So far,
recombinant monomeric gp120 or oligomeric/trimeric gp140
glycoproteins have failed to elicit broad and potent neutralizing
antibodies in experimental animal models. Therefore, rationale
structural alterations to soluble Env for effective presentation of
conserved ‘neutralizing’ epitopes represent an important strategy
towards HIV-1 vaccine development. Described herein is a
practical approach of eliciting CD4i epitope-directed virus
neutralizing antibodies using a stably cross-linked complex of
recombinant oligomeric gp140 andminiCD4 (M64U1-SH) [27,28],
to target the conserved co-receptor binding site of the HIV-1 Env.
In earlier studies, two CD4 mimetic miniproteins (miniCD4)
were cross-linked to various forms of HIV-1 Env [27,28]. Based on
results from those studies, the M64U1-SH miniCD4 was selected
here for generating the cross-linked gp140-miniCD4 (gp140-S-S-
M64U1) complex. Importantly, we observed that formation of a
stable covalent complex by cross-linking of miniCD4 and gp140
protein via disulfide bond formation [27] resulted in significantly
higher-titers of CD4i epitope-directed binding and virus neutral-
izing antibodies in rabbits immunized with the cross-linked
(gp140-S-S-M64U1) complex, not seen in animals that received
a ‘bench-side’ mixing of miniCD4 and gp140 (gp140+M64U1).
Nevertheless, both miniCD4 groups [cross-linked or mixed]
elicited antibodies of higher avidities (Fig. 3B) than the gp140
alone group, potentially contributing to the improved virus
neutralization seen with 2wp3/2wp4 sera from the (cross-linked
or mixed) complexes (Fig. 4).
Figure 6. Neutralization of HIV-2 in the presence and absence of sCD4. Individual rabbit sera from the four groups (immunized with either
gp140, miniCD4 M64U1, cross-linked gp140-S-S-M64U1 complex or mixed gp140+M64U1 complex) were tested for neutralizing activity against the
isolate 7312A/V434A in the absence (open bars) or presence (filled bars) of sCD4. The ID50 neutralization titers are shown for the pre-immune (black),
2wp3 (red), and 2wp4 (blue) serum samples. The antigens used for immunization are indicated above each graph. Dashed lines indicate the lowest
dilution tested.
doi:10.1371/journal.pone.0030233.g006
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Moreover, rabbits immunized with the cross-linked gp140-S-S-
M64U1 complex elicited antibodies targeted to the CD4i
epitope(s) while those immunized with gp140 alone or mixed
(gp140+M64U1) complex did not. By ‘serum mapping’ experi-
ments, it appeared that the majority of the animals (except the
control group immunized with the miniCD4) elicited V3-specific
antibodies. Only one animal in the gp140-immunized group
elicited CD4BS antibodies (Fig. 5A) and all animals (5/5)
immunized with cross-linked gp140-S-S-M64U1 complex elicited
CD4i epitope-directed antibodies, whereas the mixed
(gp140+M64U1) complex did not. This observation of selective
elicitation of CD4i epitope-directed antibodies was confirmed by
the HIV-2 neutralization assay (Fig. 6).
Subtype B immunogens, such as the SF162 gp140 used here,
elicit substantial levels of anti-V3 antibodies that can be blocked by
subtype-specific V3 peptide [49]. In addition, Env undergoes a
conformational change upon CD4 binding that results in the
relocation of the inner domain of gp120 to the molecular surface
and exposure of V3 loop from the core domain to the solvent-
accessible surface of gp120 [50,51]. Therefore, the induction of
anti-V3 antibody responses by the gp140-miniCD4 [gp140-S-S-
M64U1 (cross-linked) and gp140+M64U1 (mixed)] complex
immunogens was evaluated using a competition assay that
employed V3-cyclic peptide (Fig. 5D). While over 80% of the
gp140-specific binding activity of sera from gp140-immunized
group was inhibited by V3-peptide, only about 20% of the binding
activity of sera from both gp140-miniCD4, cross-linked and
mixed, complex immunogen immunized animals was inhibited by
V3-peptide. This observation that the elicitation of anti-V3
antibodies was not enhanced by both gp140-miniCD4 complex
immunogens was also supported by HxB2-neutralization results.
Sera from both the gp140-miniCD4, cross-linked or mixed,
complex immunized groups neutralized HxB2, a virus that is not
sensitive to anti-V3 antibodies [49], more potently (although
without statistical significance) than sera from the group that was
immunized by gp140 alone (Fig. 4). These data suggested that the
structural alterations upon Env-CD4 protein binding and
alterations upon gp140-miniCD4 interaction may differ concern-
ing V3 loop exposure and subsequent V3-specific antibody
elicitation. In addition, the results here also confirm that the
breadth and potency by sera from cross-linked (gp140-S-S-
M64U1) complex group is likely due to the elicitation of antibodies
directed to CD4i epitope(s) rather than to the V3 loop. Hence, the
use of a stable, covalently cross-linked complex of gp140 and
miniCD4 appears to represent a viable method for the elicitation
of higher titer antibodies directed to conserved CD4i epitope(s) on
HIV-1 Env.
It was reported previously that some CD4i full-length antibodies
encounter steric hindrances in accessing the ‘induced’ epitope on
viral envelope glycoprotein available post-CD4 attachment, due to
constrained space between the cell and the viral membrane
following (viral) Env and (cellular) CD4 interaction [17].
Nevertheless, numerous studies have reported the elicitation of
high titers of CD4i antibody during natural human infection
against multiple HIV-1 subtypes and circulating recombinant
forms (CRFs). Importantly, these antibodies bind and neutralize
not only various HIV-1 isolates but also HIV-2 in CD4-induced
manner [23], indicating the functional constraints on receptor
binding that create opportunities for broad humoral immune
recognition and neutralization of viral quasispecies. Although
speculations could be made as to how these antibodies are so
commonly generated and how they neutralize various HIV-1
isolates, the precise in vivo mechanism, more importantly in
neutralization, is unknown.
The elicitation of CD4i antibodies signifies the extraordinary
degree of antigenic conservation linked to co-receptor binding
exhibited by diverse HIV-1 and HIV-2 lineages, and at the same
time, the ability of human humoral immune system to exploit
these constraints [23]. But since humoral response determined by
analyzing circulating antibodies are likely to change significantly
over time, due to the high mutability of HIV-1 envelope, this
measure in sera is unlikely a reflection of long-term protection.
Rather analyses of memory B-cell compartment may be more
telling about protective immunity. Recently, Y Guan et al.
reported that although ‘‘elite controllers’’ showed low level of
circulating antibody response against CD4i epitope(s), CD4i
epitope-specific B lymphocyte memory cells were present at high
frequencies (greater than a third of the anti-Env antibodies) in all
‘elite controllers’ subjects tested [52]. Besides, similar conclusion
on broader diversity of anti-HIV-1 antibodies isolated from
memory B-cells have been echoed by JF Scheid et al. [53], in
which $15% of the neutralizing antibodies were directed to the
CD4i epitope(s). The induction of CD4i Abs in patients infected by
HIV-1 [22,23,52] highlights the exposure of the co-receptor
binding site on the virus surface, which may occur after binding of
gp120 to CD4 on the target cell despite the steric hindrance
reported by Labrijn et al. [17], or because of CD4-independent
variants exposing the co-receptor binding site in most of the
infected patients [10,54]. Presence of circulating soluble CD4 or of
CD4-gp120 complexes at the surface of targeted cells, following
shedding of gp120 from gp41 and consequently from the virus
particle following HIV-1 binding to CD4, could also contribute to
elicitation of CD4i antibodies, as most recently exemplified in
primates [55]. Overall, these and other studies highlight the role of
CD4i antibodies during the course of HIV-1 infection.
In the past, several studies have been performed, based on
gp120-CD4 (or CD4 mimic) complexes or constrained ‘core’
gp120 antigens as vaccine candidates, aiming at inducing CD4i
antibodies [18,19,56,57,58]. T Fouts et al. showed that gp120
cross-linked to CD4 D1D2 domains raised antibodies that
neutralized primary viruses regardless of co-receptor usage and
genetic subtype in nonhuman primates [18]. These findings were
extended in a challenge study by A DeVico et al. [19], where
macaques immunized with a single chain complex containing
gp120BaL-rhesus macaque CD4 D1D2 showed better CD4i
antibody response that correlated with the control of infection
when challenged with SHIV162P3. Although this correlation is
not a proof of the neutralizing efficiency of CD4i antibodies, it
shows that the presence of these MAbs is fully related to the CD4-
bound conformation of HIV-1 envelope in vivo. Besides, recent
approach towards constraining ‘gp120 core’ protein by site-
directed disulfide linkage(s) has been a novel step towards eliciting
epitope-specific response against the co-receptor binding site [58].
These vaccination studies indicate the potential importance of
strategies directed to raising antibodies against the CD4i site.
Some success in protection against HIV-1 acquisition has been
afforded by active prophylactic vaccination using either DNA
prime-recombinant Env protein boost [59,60] or viral vector
prime-recombinant Env protein boost [61,62,63,64,65,66] or
adjuvanted recombinant Env proteins [67,68] in studies per-
formed in nonhuman primate models, and most recently, in
humans using a Canarypox vector prime plus recombinant Env
protein boost approach in the RV144 Phase III trial performed in
Thailand [69]. Recent correlates of risk assessments of the RV144
trial indicated that V1V2-directed IgG antibodies in sera from
vaccinees were associated with vaccine-elicited protection [70].
Despite this early ‘‘hypothesis generating’’ finding in this first
promising HIV-1 vaccine trial, the importance of the diversity of
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antibodies elicited by other epitopes on Env such as the CD4i
epitope(s) [71], during infection and vaccination, and their role in
immune protection against HIV-1 infection warrant further
investigation.
The present work provides a powerful next generation approach
using a novel and stable cross-linked complex of oligomeric gp140
glycoprotein and a CD4 mimetic miniprotein, in order to elicit
broadly reactive functional antibody responses targeted to the
highly conserved co-receptor binding site of the HIV-1 Env.
Moreover, it does so while avoiding the elicitation of undesirable
anti-CD4 reactivity. This cross-linked gp140-miniCD4 (gp140-S-
S-M64U1) complex is suitably stable for future vaccine studies in
non-human primate models, and represents a viable strategy
for further evaluations of the role of CD4i epitope-directed
antibody responses in protection against HIV-1 infection during
vaccination.
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